endstream endobj startxref We comply with the HONcode standard for trustworthy health information - Daklinza ™ (daclatasvir) – Product discontinuation January 4, 2019 - The FDA announced the discontinuation of Bristol Myers Squibb’s Daklinza (daclatasvir) 30 mg and 60 mg tablets. The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. The number of patients that required invasive mechanical ventilation was three in the treatment arm and seven in the control arm (P = 0.303). — Previously, the FDA announced the discontinuation of Daklinza 90 mg tablets with planned distribution ceasing in December 2018.
$����3 ٛ@�� (daclatasvir) 30 mg and 60 mg tablets. Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS; DAKLINZA: DACLATASVIR DIHYDROCHLORIDE: EQ 30MG BASE: TABLET;ORAL: Discontinued h�b``b``Z� 5�P#�0p4 � A1C/�&��F��QI�")�s0XHo�}X�nH�d�|L36��e��fT 0 C0 Development Timeline for Daklinza It is taken by mouth once a day. 0 %%EOF Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Gavreto (pralsetinib) is an oral selective RET kinase inhibitor for the...Detectnet (copper Cu 64 dotatate) is a radioactive diagnostic agent indicated...Onureg (azacitidine) is a nucleoside metabolic inhibitor indicated for the...Qdolo (tramadol hydrochloride) is an opioid agonist indicated in adults for ...The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. — Bristol Myers Squibb has planned to cease distribution for Daklinza 30 mg and 60 mg tablets in June 2019. Of the three deaths in the treatment arm, two had sofosbuvir/daclatasvir discontinued by the physician after 1 and 2 days for respiratory failure and pulmonary thromboembolism, respectively. Select one or more newsletters to continue.
Daclatasvir, sold under the trade name Daklinza, is a medication used in combination with other medications to treat hepatitis C (HCV).
�Y
70 0 obj <>/Filter/FlateDecode/ID[<08962BCF79B64E49BEC47E210B7B92F8><80BAB096F85E3A4DA622FA6D690BC58D>]/Index[50 52]/Info 49 0 R/Length 97/Prev 38101/Root 51 0 R/Size 102/Type/XRef/W[1 2 1]>>stream
Generic name: daclatasvir Dosage form: Tablets Company: Bristol-Myers Squibb Company Treatment for: Hepatitis C. Marketing Status: Discontinued. endstream endobj 51 0 obj < — All Daklinza tablets are now discontinued.
101 0 obj <>stream
Available for Android and iOS devices. �U�Ab�@�3�$�"�C��� 2EH�� ������00*�?��� ��|
Download PDF 50 0 obj <> endobj
h�bbd``b`�$���. %PDF-1.5 %����